GlassScriptPhysician profile
Jeffrey Lee Winston
NPI 1003938598
$16,296.86
in general payments reported to CMS, 2019-2025
36 companies · $3,979 in 2025
The $3,979 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $1,263 · 2021: $1,725 · 2022: $2,017 · 2023: $2,959 · 2024: $2,751 · 2025: $3,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,567 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,566.75 |
| Education | $122.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,681.61 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,306.41 | 2019-2025 | Rexulti, Brintellix |
| Abbvie INC. | $1,264.84 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,251.90 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $1,250.23 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $1,224.56 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $1,021.59 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $984.36 | 2020-2025 | Caplyta |
| Tris Pharma INC | $721.27 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $614.00 | 2019-2025 | Adzenys Xr-Odt, Exxua, Cotempla Xr-Odt |
| Alkermes, INC. | $573.03 | 2023-2025 | Aristada, Lybalvi |
| Allergan, INC. | $544.07 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $472.46 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $413.29 | 2019-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $370.79 | 2022-2025 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $321.07 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $283.16 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $278.18 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $244.50 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $165.55 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $139.96 | 2023-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $137.30 | 2025 | Jornay Pm |
| Neuronetics, INC. | $135.31 | 2019-2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $125.85 | 2019-2024 | |
| Adlon Therapeutics L.P. | $123.52 | 2019-2021 | |
| Shire North American Group INC | $119.24 | 2019 | |
| Livanova USA, INC. | $112.00 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.97 | 2021-2025 | Abilify Maintena |
| Brainsway USA INC | $59.04 | 2019-2024 | Brainsway Deep Tms System |
| Arbor Pharmaceuticals, INC. | $58.36 | 2019-2021 | |
| Aytu Biopharma, INC. | $51.93 | 2021-2022 | |
| Alfasigma USA, INC. | $38.49 | 2020 | |
| Merck Sharp & Dohme LLC | $36.64 | 2020 | |
| Janssen Scientific Affairs, LLC | $36.49 | 2019 | |
| Noven Therapeutics, LLC | $21.41 | 2024 | Secuado, Xelstrym |
| Orexo US, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.